Large trial finds adding an ARB to an ACE-I does not help diabetic nephropathy

MOspace/Manakin Repository

Breadcrumbs Navigation

Large trial finds adding an ARB to an ACE-I does not help diabetic nephropathy

Please use this identifier to cite or link to this item: http://hdl.handle.net/10355/7447

[+] show full item record


Title: Large trial finds adding an ARB to an ACE-I does not help diabetic nephropathy
Author: Stevermer, James J.; Misra, Shamita
Keywords: combination therapy
Date: 2009-04
Publisher: Family Physicians Inquiries Network
Citation: Evidence Based Practice 12(4): 01-02.
Abstract: While some evidence suggests that combining angiotensin converting-enzyme inhibitors (ACE-Is) and angiotensin receptor blockers (ARBs) might have clinically important benefits in some situations (particularly for patients with severe congestive heart failure [CHF]), a recent large randomized controlled trial (RCT) recently found no tangible benefit to combination therapy in patients with diabetes or arteriosclerotic cardiovascular disease without heart failure.
URI: http://hdl.handle.net/10355/7447

This item appears in the following Collection(s)

[+] show full item record